全文获取类型
收费全文 | 197161篇 |
免费 | 2682篇 |
国内免费 | 77篇 |
专业分类
耳鼻咽喉 | 1515篇 |
儿科学 | 7371篇 |
妇产科学 | 3352篇 |
基础医学 | 18721篇 |
口腔科学 | 2042篇 |
临床医学 | 14348篇 |
内科学 | 35523篇 |
皮肤病学 | 1200篇 |
神经病学 | 17572篇 |
特种医学 | 9951篇 |
外国民族医学 | 1篇 |
外科学 | 33070篇 |
综合类 | 2629篇 |
一般理论 | 15篇 |
预防医学 | 19113篇 |
眼科学 | 3532篇 |
药学 | 11352篇 |
中国医学 | 661篇 |
肿瘤学 | 17952篇 |
出版年
2023年 | 223篇 |
2022年 | 401篇 |
2021年 | 986篇 |
2020年 | 475篇 |
2019年 | 824篇 |
2018年 | 22727篇 |
2017年 | 17886篇 |
2016年 | 20030篇 |
2015年 | 1540篇 |
2014年 | 1765篇 |
2013年 | 1888篇 |
2012年 | 8585篇 |
2011年 | 22547篇 |
2010年 | 19560篇 |
2009年 | 12237篇 |
2008年 | 20627篇 |
2007年 | 22754篇 |
2006年 | 1570篇 |
2005年 | 3047篇 |
2004年 | 4160篇 |
2003年 | 5004篇 |
2002年 | 3050篇 |
2001年 | 836篇 |
2000年 | 944篇 |
1999年 | 637篇 |
1998年 | 350篇 |
1997年 | 331篇 |
1996年 | 220篇 |
1995年 | 237篇 |
1994年 | 205篇 |
1993年 | 152篇 |
1992年 | 301篇 |
1991年 | 365篇 |
1990年 | 368篇 |
1989年 | 285篇 |
1988年 | 258篇 |
1987年 | 256篇 |
1986年 | 213篇 |
1985年 | 205篇 |
1984年 | 129篇 |
1983年 | 146篇 |
1982年 | 109篇 |
1981年 | 70篇 |
1980年 | 97篇 |
1979年 | 131篇 |
1978年 | 85篇 |
1977年 | 72篇 |
1974年 | 84篇 |
1973年 | 89篇 |
1970年 | 77篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Pilar Nicolás 《Hereditary cancer in clinical practice》2007,5(3):144-152
The specific characteristics of genetic data lead to ethical-legal conflicts in the framework of genetic diagnosis. Several international organisations, including UNESCO and the Council of Europe, have enacted rules referring to the use of genetic information. This paper discusses possible legal and ethical criteria that could be used in genetic testing. 相似文献
22.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
23.
24.
Sergio Barroilhet Adrián Cano-Prous Salvador Cervera-Enguix Maria João Forjaz Francisco Guillén-Grima 《Social psychiatry and psychiatric epidemiology》2009,44(12):1051-1065
Introduction
This paper presents the results of a study on the psychometric properties of an authorized Spanish version of the McMaster Family Assessment Device, a self-report measure of family functioning. 相似文献25.
26.
27.
Introduction
Although ependymoma is the third most common pediatric brain tumor, we know little about the genetic/epigenetic basis of its initiation, maintenance, or progression. This is due in part to the heterogeneity of the disease, as well as the small sample size of the cohorts analyzed in most studies. 相似文献28.
Peter Angelos 《World journal of surgery》2009,33(4):609-611
29.
Kentaroh Miyoshi Minoru Naito Tsuyoshi Ueno Shinji Hato Hideo Ino 《General thoracic and cardiovascular surgery》2009,57(11):629-632
A benign esophageal leiomyoma with abnormally increased fluorine-18-fluorodeoxyglucose uptake on positron emission tomography
(PET) was resected thoracoscopically. The tumor, of which the maximum standardized uptake value of the lesion was 4.7, was
well defined and 38 mm in diameter. Neither mitotic activity nor degeneration was found histologically; and immunoreactivity
for CD34, CD117, MIB-1, and glucose transporter-1 was negative immunohistochemically. A diagnosis of gastrointestinal stromal
tumor was ruled out by an oncogenic kinase gene mutation study. This case cautions against PET-dependent evaluation for malignant
potential of esophageal submucosal tumors. 相似文献
30.